Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verrica PharmaceuticalsSTU:1NE0 +4.18%49 Days Inventory is 214.66 as of Mar. 2026, which is 14% below its 10-year median of 249.22. GuruFocus rates STU:1NE0 with a GF Score™ of 49/100 and a GF Value™ of €11.91 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 637 Biotechnology companies, Verrica Pharmaceuticals ranks worse than 57.61% on this metric.
The historical rank and industry rank for Verrica Pharmaceuticals's Days Inventory or its related term are showing as below:
STU:1NE0'
s Days Inventory Range Over the Past 10 Years
Min: 215.55 Med: 249.22 Max: 500.04
Current: 215.55
During the past 10 years, Verrica Pharmaceuticals's highest Days Inventory was 500.04. The lowest was 215.55. And the median was 249.22.
STU:1NE0's Days Inventory is ranked worse than 57.61% of 637
companies
in the Biotechnology industry
Industry Median: 183.16
vs STU:1NE0: 215.55
Verrica Pharmaceuticals's Days Inventory
declined
from Mar. 2025 (522.54) to Mar. 2026 (214.66).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Verrica Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.43.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Verrica Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.42.
Verrica Pharmaceuticals (STU:1NE0) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Verrica Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Verrica Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Verrica Pharmaceuticals Days Inventory Related Terms
Verrica Pharmaceuticals Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1NE0 vs HRTX, RLYB, CSBR: Days Inventory Comparison
For the Biotechnology subindustry, Verrica Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verrica Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Verrica Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verrica Pharmaceuticals (STU:1NE0) has a Days Inventory of 214.66 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Verrica Pharmaceuticals and its competitors. This is 14% below median its historical median of 249.22. Over the past decade, Verrica Pharmaceuticals' Days Inventory has ranged from 215.55 to 500.04. According to the industry distribution chart, Verrica Pharmaceuticals ranks #367 out of 637 companies in the Biotechnology industry, placing it in the top 57.6%.
Is Verrica Pharmaceuticals' Days Inventory too high?
Verrica Pharmaceuticals' current Days Inventory of 214.66 is 14% below median its 10-year median of 249.22. Over the past 10 years, this metric has ranged from a low of 215.55 to a high of 500.04. The Biotechnology industry median Days Inventory is 183.16. Verrica Pharmaceuticals' value of 214.66 is 17.2% above this industry median. Based on the distribution chart, Verrica Pharmaceuticals ranks #367 out of 637 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Verrica Pharmaceuticals has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verrica Pharmaceuticals' Days Inventory compare to HRTX and RLYB?
According to the Biotechnology industry distribution chart, Verrica Pharmaceuticals ranks #367 out of 637 companies for Days Inventory. This places Verrica Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 183.16. Verrica Pharmaceuticals' value of 214.66 is 17.2% above this benchmark. Historically, Verrica Pharmaceuticals' own Days Inventory has ranged from 215.55 to 500.04 over the past decade. While the company's 10-year median is 249.22 vs. the industry median of 183.16, Verrica Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.16, based on 637 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verrica Pharmaceuticals's current Days Inventory of 214.66 is 17.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Verrica Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 183.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verrica Pharmaceuticals's current Days Inventory is 214.66, which is 14% below median its own 10-year median of 249.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verrica Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Verrica Pharmaceuticals (STU:1NE0) is currently considered Possible Value Trap. The stock's GF Value™ is €11.91, compared to a current price of €4.61 — trading 61.3% below its estimated fair value. The current Days Inventory is 214.66, which is 14% below median its 10-year median of 249.22 and 17.2% above the Biotechnology industry median of 183.16. Verrica Pharmaceuticals' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Verrica Pharmaceuticals (STU:1NE0), the current Days Inventory is 214.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Verrica Pharmaceuticals (STU:1NE0) Overvalued in 2026?
Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.61 is trading 61.3% below its estimated GF Value™ of €11.91.
GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.
Key valuation signals for STU:1NE0:
Days Inventory: 214.66 (14% below median its 10-year median of 249.22)
GF Value™: €11.91 vs. price of €4.61 (61.3% below fair value)
Industry Position: 17.2% above the Biotechnology median (#367 of 637)
No single metric tells the full story. See the STU:1NE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
49GF Score
Get the complete analysis for STU:1NE0
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1NE0 has been successfully added to your 
